# rSIFN-co in Combination With Total Neo-adjuvant Therapy in Subjects With Mid-low Locally Advanced Rectal Cancer

> **NCT07662278** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sichuan Huiyang Life Science and Technology Corporation** · enrollment: 90 (estimated)

## Conditions studied

- Mid-low Locally Advanced Rectal Cancer

## Interventions

- **DRUG:** Recombinant Super-Compound Interferon (rSIFN-co)
- **DRUG:** Total Neo-adjuvant therapy

## Key facts

- **NCT ID:** NCT07662278
- **Lead sponsor:** Sichuan Huiyang Life Science and Technology Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01
- **Primary completion:** 2030-01
- **Final completion:** 2030-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662278, "rSIFN-co in Combination With Total Neo-adjuvant Therapy in Subjects With Mid-low Locally Advanced Rectal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07662278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*